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CMV infections cause signiﬁcant morbidity & mortality,
particularly among HLA mismatched HSCT recipients.
Adoptive immunotherapy using donor derived CMV-Speciﬁc
cytotoxic T-cells (D-CMV-CTLs) can treat CMV infection in
such patients. However, D-CMV-CTLs cannot be generated
for HSCT recipients from CMV seronegative donors, and
generation of such T-cells (TC) from cord blood has been
difﬁcult. Furthermore, D-CMV-CTLs in recipients of HLA
disparate HSCT maybe ineffective if the HLA allele restricting
their cytotoxic activity is not shared between the donor and
host. In these conditions, persistent CMV reactivation can be
treated using pre-generated CMV-CTLs of deﬁned epitope
speciﬁcity and HLA restriction from third party donors.
Many HLA antigens (ags) have multiple allelic variants.
We asked if TC speciﬁc for epitopes of CMVpp65 presented
by one allelic variant might also recognize the same epitope
presented by other variants of the same HLA ag. We char-
acterized the epitope speciﬁcities and HLA restrictions of 105
CMV-CTLs generated and banked for a phase I clinical trial,
plus 41 additional donors. CMV-CTLs in 37 HLA A0201+
donors were consistently responsive to the A0201 presented
NLV epitope. These NLV responsive TC from HLA
A0201+donors were also cytotoxic against NLV loaded targets
expressing HLA A0201, 0205 and 0206, but not HLA 0202,
0211 and 0220. In 13 donors expressing HLA B40, B44 and
B42 ag, CMV-CTLs were responsive to the HERNGFTVL
epitope when presented by APCs expressing any one of the
following alleles: HLA B 4001, 4002, 4006, 4401, 4403 or
4202. Importantly, CTLs from any one of these donors were
also cytotoxic against HERNGFTVL loaded targets bearing
one each of these alleles. TC from 9 donors inheriting HLA
B35, all elicited responses to the epitope EVQAIRETVE which
could be presented by either HLA B3501, 3502, 3503, 3508 or
3511; each CTL line was also cytotoxic against EVQAIRETVE
loaded targets bearing one of these HLA B35 alleles. Similar
cross reactivity was demonstrated for the QYDPVAALF
epitope which can be recognized when presented by HLA
A2402, 2404 and A2407. In contrast, allelic variants for
a given HLA class-II allele do not share epitope speciﬁc
responses in all donors; e.g. T-cells responding to the
FTSQYRIQGKL are cytotoxic against peptide loaded DRB1
1101 targets, but do not lyse FTSQYRIQGKL loaded DRB11104
targets; DRB1 1104 presents a different epitope
VAALFFFDIDL.
Our ﬁndings indicate that certain immunodominant viral
epitopes may be presented by multiple allelic variants of
class-I HLA ags. These data suggest that HLA class-I restricted
epitope speciﬁc CMV-CTLs fromHLA disparate donors can be
effective in recipients sharing certain allelic variants within
the same class-I family. Thus, generation of a bank of CTLs
responding to common immunodominant epitopes could
also potentially be used for treatment of a broader patient
population at risk for CMV.47
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Background: Conventional steroid treatment for graft versus
host disease (GvHD) is effective for a limited number of
patients (pts). The use of mesenchymal stromal cells (MSC)
as second line of treatment has been reported with prom-
ising results. We assessed the safety and efﬁcacy of MSC, in
a prospective, multicenter, phase I study (EudraCT 2008-
007869-23) for the treatment of steroid resistant grade II-IV
GvHD.
Methods:MSCwere obtained from bone marrow harvests of
third party donors and expanded with platelet lysate.
Primary endpoint of the study was safety. Secondary
endpoints were response to MSC, overall survival (OS) and
transplant-related mortality (TRM). Plasma levels of IL2Ral-
pha by ELISA were analyzed for enrolled pts.
Results: Between August 2009, and June 2012, 16 children
and 31 adults were treated. The median dose of infused MSC
was 1.5106 cells per kg. Enrolled pts presented with acute
GvHD in 37 cases, chronic overlap syndrome in 7, and chronic
classic GvHD in 3 cases. 15 pts had grade II GvHD, 23 grade III
and 9 grade IV, according to NIH criteria. In 17 cases GvHD
involved a single organ. Pts were treated with a median of 3
MSC infusions. No signiﬁcant side effects were registered. 30
patients (63.8%) showed a clinical response. 13 of them
(27.6%) had a complete response and 17 (36.1%) a partial
response to treatment. 22 over 30 responding pts did not
require further lines of immunosuppression after MSC infu-
sion. Response was more likely in pts exhibiting grade II
GvHD versus those with severer grading (87.5% vs. 51.6%, P ¼
.02) and in pts receiving MSC within 30 days from GvHD
onset (75.9% vs. 43.7%, P ¼ .05). Median follow up for this
cohort is 200 days (range 30-1066). Responders show
a signiﬁcant lower TRM (10.0% vs. 88.2%, P< .05) and a better
OS probability than non responders (23.3% vs. 88.2%, P< .05).
When comparing responders vs non-responders, IL2Ralpha
showed a statistically signiﬁcant difference in terms of fold
decrease (p¼0.027), corroborating clinical results. Similarly,
a signiﬁcant trend of fold decrease (p¼0.058) was observed
when comparing responder patients receivingMSCwithin or
after 30 days from GvHD onset, in line with clinical results.
Conclusions: This study conﬁrms that MSC may represent
a safe and effective treatment for patients with steroid-
refractory GVHD. Plasmatic markers may help in monitoring
of clinical response. We suggest to consider the use of MSC as
early as possible, after steroid failure.48
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Donor CD4+CD25+FOXP3+ regulatory T cells (Treg) are
capable of suppressing immune-mediated graft-versus-
leukemia (GvL) and graft-versus-host disease (GvHD)
responses. We undertook a dose-ﬁnding phase 1 study of
CD25-depleted donor lymphocyte infusions (DLI) to treat
post-transplantation relapse.
Methods: 24 subjects with disease relapse after HLA-
matched allogeneic transplantation (9 AML, 4 ALL, 4 HD, 2
MDS, 2 NHL) were enrolled. Patients had no evidence of
GvHD, were on no systemic immunosuppressants, and had
received no salvage chemotherapy in the 4 weeks preceding
DLI. Donor lymphocytes were CD25+ depleted via the Clin-
iMACS system (Miltenyi). Primary objectives were feasibility
and safety. Secondary objective was response.
Results - Feasibility: 3patients cameoff study for insufﬁcient
numbers of donor CD3+ cells or GvHD onset prior to DLI. In
the remainder, 10 had persistent or progressive disease, 7
were inPR, and4were inCRat studyentry. CD25-depletedDLI
doseswere 1x107 CD3+ cells/kg (level 1; n¼5) and 3x107 CD3+
cells/kg (level 2; n¼16). 8DLIswere fromunrelateddonors,13
from related donors. Median log-reductions of CD25+ and
CD4+CD25+FOXP3+Treg cells in the infusion products were
1.24 (range 0.72-7.75) and 2.10 (range 1.17-6.46), respectively.
Safety: 16 of 21 subjects were evaluable for toxicity. In 3
evaluable subjects at DLI Level 1, there were no DLTs. Dose
Level 2 was the MTD, with 1 case of fatal acute GvHD in 13
evaluable subjects.Amongall subjects, ratesofacuteorchronic
GvHD were 19% by 8 weeks and 38% by 1 year following DLI.
Response: Median follow-up is 29.5 months. All subjects at
Dose level 1 had progressive disease at 8 weeks; 1 experi-
enced extensive chronic GvHD. At Dose level 2, 8 subjects
(50%) had a response (1 PR, 7 CR), including 6 who had
evidence of disease at DLI. 6 subjects, including 5 responders,
manifested GvHD by day 100. 1 year survival was 8/16 (50%)
in the MTD cohort, with 4 of the initial 8 week responders
still in CR. Median survival was 15.4 months.
Conclusions: Use of CD25+ Treg depleted DLI appears
feasible, safe and capable of inducing GvL without excessive
GvHD in hematologic malignancies relapsed after allo-
transplantation. Its safety and preliminary efﬁcacy is prom-
ising but needs future prospective evaluation.Table 1
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In previous work, we found that CD27+ B cells from
patients with chronic GVHD (cGVHD) are metabolically
active and capable of constitutive IgG production via BAFF-
associated pathways. As B Cell Receptor (BCR) signaling is
vital for B cell survival and activation, we hypothesized that
antigen engagement of BCR confers distinct signaling in
potentially pathologic CD27+ B cells in human cGVHD. We
ﬁrst aimed to identify candidate genes using pathway-
focused mRNA expression proﬁling of highly puriﬁed CD27+
and CD27- B cell populations from 3 patients with cGVHD
and 3 healthy individuals. A unique array signature was
identiﬁed, conﬁrming that circulating CD27+ B cells in
cGVHD are distinct from healthy 'memory' B cells. Of the 89
genes examined, 3 transcripts were signiﬁcantly increased in
CD27+ B cells from patients with cGVHD compared to
healthy individuals. B-cell linker protein (BLNK), down-
stream of BCR ligation, was signiﬁcantly increased 5.5 fold
(p¼0.01) in CD27+ B cells from patients with cGVHD
compared to CD27+ B cells in healthy individuals. BLNK was
also increased 5-fold (p¼0.001) in CD27- B cells from
patients with cGVHD compared to CD27- B cells from healthy
individuals. Intracellular ﬂow cytometry veriﬁed that stim-
ulation of BCR resulted in increased expression of BLNK
protein in 3 healthy individuals at 36 (p¼0.01) and 60
(p¼0.03) hours. To extend these ﬁnding to patients with
cGVHD compared to patients without cGVHD we studied
puriﬁed, un-manipulated CD19+ B cells from 10 HSCT
patients who were >12 months post-transplant and off high
dose steroid. cGVHD (n¼4) B cells had signiﬁcantly increased
protein expression of BLNK (p¼0.005) compared to B cells
from patients without cGVHD (n¼6). The protein kinase Syk,
upstream of BLNK, was also signiﬁcantly increased in B cells
from cGVHD patients (p¼0.01) compared to B cells from
patients without disease. These data suggest that B cells in
cGVHD are hyper-responsive to antigen (Table 1). To deter-
mine if B cells trafﬁc to lesional tissue, liver biopsies were
immunohistochemically analyzed in 3 patients with cGVHD.
Two of 3 patients with disease had detectable CD27+ and
CD27- B cells in the liver while 2 reference biopsies from
acute hepatitis patients, without cGVHD, did not. This afﬁrms
that BCR-activated B cells can be found at cGVH disease sites.
Increased expression of BLNK and Syk in B cells from patients
